Company Overview and News

30
Recent IPO Replimune: Oncolytic Viral Technology

2018-08-28 seekingalpha
Woburn, Massachusetts based Replimune launched its NASDAQ IPO recently, offering 7.4M shares at $15/share, raising $105M.
NKTR REGN AMGN RARX

7
7
Ra Pharmaceuticals: Is Trying To Copy What Works A Good Product Development Strategy?

2018-07-30 seekingalpha
Ra Pharma is developing RA101495, a C5 inhibitor and a potential competitor to Alexion's blockbuster Soliris.
RARX

12
Insiders Are Bullish On Tiny Tonix (Again)

2018-07-24 seekingalpha - 5
TNXP remains appropriate only for investors who can stomach the high risk in this potentially high-reward punt.
RARX TNXP

8
Riding Ra Pharmaceuticals

2018-07-23 seekingalpha
Shares of Ra Pharmaceuticals (NASDAQ:RARX) have so far been a classically successful insider-inspired investment idea, with the volatility of this high-risk/high-reward development-stage biotech definitely biased to the upside so far in our 5-month holding period.
ALXN RARX

72
6 Speculative BioHealth Analyst Stocks That Could Rally 50% to 300%

2018-07-21 247wallst - 17
The bull market is now more than nine years old. Many investors have begun looking for new ideas and new strategies to generate income and gains, and the old strategy of buying every major market selling day has become less rewarding in 2018 versus the prior few years. It turns out that Wall Street brokerages and research shops still have many stock picks for big upside.
EIDX MGTA INNT GLMD RARX SNDX

51
Top Analyst Upgrades and Downgrades: AEP, Facebook, Microsoft, PayPal, Philip Morris, Spotify, Under Armour and More

2018-07-20 247wallst - 2
Stocks were indicated lower on Friday on more China woes, but it’s been a choppy time of late. The investing community has had less faith and has seen lower rewards from buying the dips in 2018 than in prior years. Many of those same investors also have been concerned about how they want their investments positioned ahead of the midterm elections, into international trade concerns and into 2019 and beyond.
WFCNP PM FB GLMD UAA PYPL SKX SPOT AEP MS WFC YUMC ISRG ETR UA SIX FDC RARX TRI MSFT ESRX

24
RARX / Ra Pharmaceuticals, Inc. 8-K (Current Report)

2018-06-29 sec.gov - 6
UNITED STATES
RARX

29
RARX / Ra Pharmaceuticals, Inc. 8-K (Current Report)

2018-06-07 sec.gov - 11
UNITED STATES
RARX

148
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

2018-05-31 seekingalpha - 2
This article is the second of two parts discussing Alexion Pharmaceuticals (ALXN) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXN’s competition. I have previously reviewed a large number of ALXN’s competitors back in October, 2017, but there have been some important developments since worth reviewing. Further, given the recent phase 3 success of ALXN1210 in paroxysmal nocturnal hemoglobinuria (PNH), and with results in atypical hemolytic uremic syndrome (aHUS) coming in Q4’18, it now becomes prudent to compare the competitors' drugs to ALXN1210, not just Soliris.
OMER MOR MPSYF ALXN AKTX MPSYY CLTX RARX ACHN APLS

225
5 Clinical-Stage Biotech Stocks to Buy Under $10

2018-05-29 investorplace - 5
Not many sectors offer the potential for big time gains like biotech. Especially when you’re looking at smaller clinical-stage names. After all, the thrill of getting a big-time approval or even making through to the next round of FDA trail phases can send a biotech stock’s price surging. Conversely, one mishap can send shares crashing.
OCUL AMGN GALTW JNJ ZFGN GALTU RARX VKTX GALT

22
RARX / Ra Pharmaceuticals, Inc. 8-K (Current Report)

2018-05-09 sec.gov - 4
UNITED STATES<
RARX

21
RARX / Ra Pharmaceuticals, Inc. 424B5 (Prospectus)

2018-05-09 sec.gov - 3
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
RARX

18
RARX / Ra Pharmaceuticals, Inc. S-8

2018-05-09 sec.gov
As filed with the Securities and Exchange Commission on May 9, 2018 Registration No. 333-
RARX

20
RARX / Ra Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-05-09 sec.gov - 2
Table of Contents
RARX

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 74933V108